Business
Buscar Company's Subsidiary Armorgenix Appoints Eric Sauer as Chief Operating Officer to Drive Innovation in Natural Health and Pharmaceutical Solutions
Buscar Company's Subsidiary Armorgenix Appoints Eric Sauer as Chief Operating Officer to Drive Innovation in Natural Health and Pharmaceutical Solutions.
About this update from Buscar Company
[{"type":"text","content":"\r\n\r\n \r\n \r\n Buscar Company's Subsidiary Armorgenix Appoints Eric Sauer as Chief Operating Officer to Drive Innovation in Natural Health and Pharmaceutical Solutions\r\n \r\n \r\n\r\n\r\nBuscar Company's Subsidiary Armorgenix Appoints Eric Sauer as Chief Operating Officer to Drive Innovation in Natural Health and Pharmaceutical Solutions\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nBEVERLY HILLS, Calif., Aug. 27, 2025 /PRNewswire/ -- Armorgenix, a subsidiary of Buscar Company (OTC: CGLD), today announced the appointment of Eric Sauer, RPh, DHPh, as its new Chief Operating Officer (COO). This strategic hire comes on the heels of Buscar's acquisition of a 70% stake in Armorgenix in June 2025, further strengthening the company's diversified portfolio in natural resources, sustainable technologies, and innovative pharmaceuticals. With over 40 years of experience in pharmacy, naturopathy, and holistic medicine, Sauer will play a pivotal role in advancing Armorgenix's portfolio of enzyme-based therapies, compounded natural remedies, detoxification solutions like DetoxShield, and antiviral products, aligning with Buscar's mission to address global health and environmental challenges through high-growth innovations.\r\n\r\n \r\n \r\n \r\n \r\n \r\n \r\n\r\n \r\nIn his new role, Sauer will oversee daily operations, strategic planning, product development, and the expansion of Armorgenix's manufacturing capabilities, including the planned Texas-based facility and Wyoming-based corporation for intellectual property management. His expertise ensures Armorgenix delivers high-quality, science-backed natural alternatives that complement conventional medicine, while supporting Buscar's broader goals of market penetration in the U.S. antiviral and detoxification sectors. Sauer's focus on client education, medication safety, and alternative therapies perfectly complements Armorgenix's clinically evaluated products and Buscar's commitment to delivering long-term shareholder value.\r\n\"Eric Sauer's unique blend of traditional pharmaceutical knowledge and holistic expertise makes him an ideal leader for Armorgenix at this transformative stage,\" said Alexander Dekhtyar CEO of Buscar Company. \"Under Buscar's umbrella, we are poised to scale our operations in enzyme therapy, clinical nutrition, and antiviral solutions. Eric's insights will help us inte...